The 20 Best Non-Muscle Invasive Bladder Cancer Doctors Near Me

Ashish Kamat is a Urologist in Houston, Texas. Dr. Kamat is rated as an Elite provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy.

Gary Steinberg is a Urologist in Crown Point, Indiana. Dr. Steinberg is rated as an Elite provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Ureteral Reconstruction. Dr. Steinberg is currently accepting new patients.

Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic. He earned his medical degree from Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer. Dr. Lerner is author of more than 160 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. Dr. Lerner is an active member of the prestigious American Association of Genitourinary surgeons and is listed routinely among America's Top Doctors and Best Doctors in America. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor, and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, targeted molecular therapeutics, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 22 years of experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy for muscle invasive bladder cancer. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, co-chair of the NCI's Bladder Cancer Task Force and the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is rated as an Elite provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy.

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Elite provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Dr. Mark A. Preston is a urologic surgeon at Brigham and Women’s Hospital and Associate Professor of Surgery at Harvard Medical School. Dr. Preston received his Medical Degree from the University of Ottawa in Canada, where he also completed his residency training in Urology. He completed a three-year accredited fellowship in Urologic Oncology at Massachusetts General Hospital including a Masters of Public Health from the Harvard School of Public Health with a concentration in clinical effectiveness. He is board certified in Urology.Dr. Preston’s clinical interests include urologic oncology (bladder, kidney, prostate and testicular cancer) and minimally invasive surgery. Dr. Preston’s research focuses on the epidemiology of prostate and kidney cancer risk with an emphasis on predictive biomarkers and pharmacoepidemiology. Dr. Preston is rated as an Elite provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Prostate Cancer, Cystectomy, and Prostatectomy.

Joshua Meeks is an Oncologist in Chicago, Illinois. Dr. Meeks has been practicing medicine for over 21 years and is rated as an Elite provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Reconstructive Urology Surgery.

. Dr. Bermejo is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Familial Prostate Cancer, Ureteroscopy, and Reconstructive Urology Surgery.

"Dr. Grant Taylor has been practicing urology in the Tri-Cities area since 2005. He says, ""We love the people in this area and the beauty around us. We enjoy outdoor activities, and this area affords us many opportunities to get outside."" Dr. Taylor's personal philosophy for treating patients is, ""Listen first and understand why they are here seeing us and the impact this issue has on them. This allows us to have aligned goals for their care."" He says, ""We all have difficult days in our lives. This is a sacred space that we as physicians are in with our patients, and we have the privilege of walking that with them and providing the kind of care we would want for our family.". Dr. Taylor is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Renal Oncocytoma, Urinary Tract Infection in Children, UPJ Obstruction, Ureteroscopy, and Reconstructive Urology Surgery.

. Dr. Beaird is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are UPJ Obstruction, Urinary Tract Infection in Children, Perirenal Abscess, Ureteroscopy, and Reconstructive Urology Surgery.

. Dr. Mcgoldrick is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Enlarged Prostate (BPH), Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Familial Prostate Cancer, and Ureteroscopy.

James Griffin is a Urologist in Elgin, Illinois. Dr. Griffin is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Perirenal Abscess, Boils, Urinary Tract Infection in Children, Ureteroscopy, and Prostatectomy.

. Dr. Rogers is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are UPJ Obstruction, Hydronephrosis, Obstructive Uropathy, Ureteroscopy, and Reconstructive Urology Surgery.

Morgan Roupret practices in Paris, France. Mr. Roupret is rated as an Elite expert by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Bladder Cancer, Nephrectomy, and Cystectomy.

James McKiernan, MD, is the John K. Lattimer Professor of Urology and CEO of ColumbiaDoctors. He is also Senior Vice Dean for Clinical Affairs for Columbia University Vagelos College of Physicians and Surgeons. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused on urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1,000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues.For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer. Dr. Mckiernan is rated as an Elite provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy.

Dr. Sima Porten is a specialist in cancers of the genital and urinary organs. She is a member of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center. Her clinical interests include the diagnosis and treatment of genitourinary cancer, particularly bladder cancer, upper tract urothelial cancer, kidney cancer and high-risk prostate cancer. Porten's research focuses mainly on the diagnosis and management of urothelial carcinoma, a cancer involving parts of the kidney, bladder and ureter (the tube connecting each kidney to the bladder). In studying the biologic or genetic basis of urothelial carcinoma, she hopes to develop new tests and treatments to bring personalized medicine to patients with bladder cancer. Porten received her undergraduate, medical and master of public health degrees from Northwestern University. During medical school, she was inducted into the Alpha Omega Alpha Honor Medical Society and also completed a fellowship through the Howard Hughes Medical Institute–National Institutes of Health Research Scholars Program. She then completed her urology residency training at UCSF, where she received the Julius R. Krevans Award for Clinical Excellence. During her training in urologic oncology at the University of Texas MD Anderson Cancer Center, she was awarded a John Quale Travel Fellowship for her research in bladder cancer. Porten is an active member of the American Urological Association, American Society of Clinical Oncology, Society of Women in Urology and Society of Urologic Oncology. Dr. Porten is rated as an Elite provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. Her top areas of expertise are Bladder Cancer, Urothelial Cancer, Non-Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Jeffrey Holzbeierlein is an Oncologist in Kansas City, Kansas. Dr. Holzbeierlein has been practicing medicine for over 32 years and is rated as an Elite provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Holzbeierlein is currently accepting new patients.

Gopal Gupta is a Urologist in Melrose Park, Illinois. Dr. Gupta is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Prostate Cancer, Nephrectomy, and Cystectomy. Dr. Gupta is currently accepting new patients.

. Dr. White is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Enlarged Prostate (BPH), Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Bladder Reconstruction, and Ureteroscopy.

. Dr. Harris is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Perirenal Abscess, Boils, Carbuncle, Ureteroscopy, and Reconstructive Urology Surgery.

Kirsten Greene is a Urologist in Charlottesville, Virginia. Dr. Greene is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Ureterocele, Nephrectomy, and Reconstructive Urology Surgery. Dr. Greene is currently accepting new patients.